Multisite Risk Assessment to Reduce MTX-Use Errors in Childhood Malignancy
ZHU Chen1, LIANG Gang1, LI Ying2, JIANG Ni3, FANG Hong-mei1, GUAN Yan1, WANG Xiao-ling2*
1. Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou 310016, China; 2. Beijing Children′s Hospital, Capital Medical University, Beijing 100045, China; 3. Dalian Children′s Hospital of Dalian Medical University, Dalian 116012, China
Abstract：OBJECTIVE Medication errors (ME) more frequently affect pediatric patients than adults. Chemotherapeutic drug MEs seems more serious and less detected, among which, the most commonly involved chemotherapeutic agent was methotrexate (MTX). To engage multidisciplinary teams of childhood malignancy in a multisite study using proactive risk assessment methods to identify how MTX errors occur and propose risk reduction strategies. METHODS We recruited doctors, nurses, pharmacists and parents from three children′s hospitals in the northeast and southeast China to participate in failure mode and effects analyses (FMEA). An FMEA is a systematic team-based proactive risk assessment approach in understanding ways a process can fail and develop prevention strategies. Steps included diagram the process, collect failure modes/risks and prioritize failure modes, and propose risk reduction strategies. We focused on MTX-use process in and out of hospitals. RESULTS A multidisciplinary medication safety team was formed of total 66 members. They developed a four-stage flow diagram with four main phases, based on which, 56 potential risks were recognized and 17 were classified as higher risks by the hazard-scoring matrix. The highest priority failure modes in hospital included wrong solvents, wrong frequency label and lake of monitoring; furthermore, errors involving excessive intake of oral MTX after discharge were worth extra attention. Meanwhile, remediation strategies were developed, consisting of constrained and recommended strategies. CONCLUSION FMEA is a useful tool to identify the risk of MTX MEs and several years later, with the concerted efforts of all the healthcare staff and technicians, we wish to see a reduction in the potential for errors being made and an improvement of children safety.
GHALEB M A, BARBER N, FRANKLIN B D, et al. Systematic review of medication errors in pediatric patients[J]. Ann Pharmacother, 2006, 40(10):1766-1776.
[2]
KAUSHAL R, BATES D W, LANDRIGAN C, et al. Medication errors and adverse drug events in pediatric inpatients[J]. Jama, 2001, 285(16):2114-2120.
[3]
MCCLEAD R E, CATT C, DAVIS J T, et al. An internal quality improvement collaborative significantly reduces hospital-wide medication error related adverse drug events[J]. J Pediatr, 2014, 165(6):1222-1229.
[4]
RINKE M L, SHORE A D, MORLOCK L, et al. Characteristics of pediatric chemotherapy medication errors in a national error reporting database[J]. Cancer, 2007, 110(1):186-195.
[5]
JOHNSTON W T, LIGHTFOOT T J, SIMPSON J, et al. Childhood cancer survival:a report from the United Kingdom Childhood Cancer Study[J]. Cancer Epidemiol, 2010, 34(6):659-666.
[6]
PUI C H. Genomic and pharmacogenetic studies of childhood acute lymphoblastic leukemia[J]. Front Med, 2015, 9(1):1-9.
[7]
MARX D A, SLONIM A D. Assessing patient safety risk before the injury occurs:an introduction to sociotechnical probabilistic risk modelling in health care[J]. Qual Saf Health Care, 2003,12(90002):33-38.
[8]
WEINGART S N, SPENCER J, BUIA S, et al. Medication safety of five oral chemotherapies:a proactive risk assessment[J]. J Oncol Pract, 2011, 7(1):2-6.
[9]
XIAO-XIA T, WEN-WEN Z, DA-KUI C. Pharmaceutical care of a patient with severe adverse events caused by MTX-use errors[J]. China Pharm(中国药师), 2014, 17(2):282-285.
[10]
YELAMOS O, CATALA A, VILARRASA E, et al. Acute severe methotrexate toxicity in patients with psoriasis:a case series and discussion[J]. Dermatology, 2014, 229(4):306-309.
[11]
ARNET I, BERNHARDT V, HERSBERGER K E. Methotrexate intoxication:the pharmaceutical care process reveals a critical error[J]. J Clin Pharm Ther, 2012, 37(2):242-244.
[12]
VERDUIJN M M, VAN DEN BEMT B J, DIJKMANS B A, et al. Methotrexate:safe if prescribed correctly[J]. Ned Tijdschr Geneeskd, 2009, 15(3):A695.
[13]
CHARFI R, SALOUAGE I, TRABELSI S, et al. Accidental shortening time of high dose methotrexate infusion:case report and literature review[J]. Ann Biol Clin (Paris), 2013, 71(2):219-222.
[14]
BYNG-MADDICK R, WIJENDRA M, PENN H. Primary care attitudes to methotrexate monitoring[J]. Qual Prim Care, 2012, 20(6):443-447.
[15]
MACKINNON S K, STARKEBAUM G, WILLKENS R F. Pancytopenia associated with low dose pulse methotrexate in the treatment of rheumatoid arthritis[J]. Semin Arthritis Rheum, 1985, 15(2):119-126.
[16]
JOINT COMMISSION ON ACCREDITATION OF HEALTHCARE ORGANIZATIONS. Using failure mode and effects analysis to meet JCAHO′s proactive risk assessment requirement. Failure Modes and Effect Analysis[J]. Health Devices, 2002, 31(6):223-226.
[17]
VAN TILBURG C M, LEISTIKOW I P, RADEMAKER C M, et al. Health care failure mode and effect analysis:a useful proactive risk analysis in a pediatric oncology ward[J]. Qual Saf Health Care, 2006, 15(1):58-63.
[18]
WALSH K E, MAZOR K M, ROBLIN D, et al. Multisite parent-centered risk assessment to reduce pediatric oral chemotherapy errors[J]. J Oncol Pract, 2013, 9(1):e1-7.
[19]
ISMP. 2016-2017 Targeted Medication Safety Best Practices for Hospitals[J/OL]. [2018-12-25]. http://www.ismp.org/tools/bestpractices/2016.
[20]
PROTECT. Put Your Medicines Up and Away and Out of Sight[J/OL]. [2018-12-25]. http://upandaway.org/2012.
[21]
GUFFEY P, SZOLNOKI J, CALDWELL J, et al. Design and implementation of a near-miss reporting system at a large, academic pediatric anesthesia department[J]. Paediatr Anaesth, 2011, 21(7):810-814.
2019, Vol. 54 
